País: Canadá
Idioma: inglés
Fuente: Health Canada
PAMIDRONATE DISODIUM
NOVARTIS PHARMACEUTICALS CANADA INC
M05BA03
PAMIDRONIC ACID
90MG
POWDER FOR SOLUTION
PAMIDRONATE DISODIUM 90MG
INTRAVENOUS
10ML
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0123608002; AHFS:
MARKETED
1999-07-19
_ _ _ _ _Page 1 of 38_ PRODUCT MONOGRAPH PR AREDIA ® (pamidronate disodium for injection) 30 mg, 90 mg For i.v. infusion only Bone Metabolism Regulator Novartis Pharmaceuticals Canada Inc. Dorval, Quebec, H9S 1A9 Date of Revision: April 17, 2014 Control No.: 172078 _ _ _ _ _Page 2 of 38_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................3 ADVERSE REACTIONS ....................................................................................................9 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................14 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................18 STORAGE AND STABILITY ..........................................................................................22 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................22 PART II: SCIENTIFIC INFORMATION ...............................................................................23 PHARMACEUTICAL INFORMATION ..........................................................................23 CLINICAL TRIALS ..........................................................................................................23 DETAILED PHARMACOLOGY .................................................................. Leer el documento completo